Transition from secukinumab to adalimumab in COVID‐19‐induced psoriasis flare‐up treatment: A case report

Coronavirus disease 2019 (COVID‐19) is known to trigger systemic inflammation and elicit immune responses, which may disrupt the delicate balance of cytokines involved in psoriatic regulation. Compared to other therapies in dermatology, biologics used for immune‐mediated dermatological diseases have...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yuting, Qiu, Yangyang, Chen, Meiqing, Huang, Ling, Lin, Xinyu, Qiu, Xiaoyan, Wei, Yi, Gao, Lujuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568048/
https://www.ncbi.nlm.nih.gov/pubmed/37841881
http://dx.doi.org/10.1002/ccr3.8047
Descripción
Sumario:Coronavirus disease 2019 (COVID‐19) is known to trigger systemic inflammation and elicit immune responses, which may disrupt the delicate balance of cytokines involved in psoriatic regulation. Compared to other therapies in dermatology, biologics used for immune‐mediated dermatological diseases have been more extensively studied during the COVID‐19 pandemic. Herein, we report a case of flare‐up of previously well‐controlled psoriasis shortly after infection with COVID‐19, with treatment transition from secukinumab to adalimumab.

Ejemplares similares